The drug tirzepatide (Mounjaro) was approved by the Food and Drug Administration for the treatment of type 2 diabetes in May 2022. It was found to help achieve blood sugar control and weight loss goals faster than other types of diabetes medications in a new study. Experts say lifestyle factors and health conditions that can increase the risk of diabetes include physical inactivity, high blood pressure, high cholesterol, smoking, and being older than 45. Type 2 diabetes is the most common type of diabetes, according to the National Institutes of Health.Read Long Article
